Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 28 Jul 2016

    Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
    Read More


  • 21 Jul 2016

    Agenus to Report Second Quarter 2016 Financial Results on July 28, 2016; Conference Call to Follow
    Read More


  • 06 Jul 2016

    Agenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development
    Read More


  • 22 Jun 2016

    Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
    Read More


  • 15 Jun 2016

    Agenus to Present at the 2016 JMP Securities Life Sciences Conference
    Read More


  • 09 Jun 2016

    Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
    Read More